Gopalakrishnan Parthasarathy

Title: Gopalakrishnan Parthasarathy: Innovator in PCSK9 Antagonists

Introduction

Gopalakrishnan Parthasarathy is a notable inventor based in Hillsborough, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the development of antagonists for human proprotein convertase subtilisin-kexin type 9 (PCSK9). His work is crucial for advancing treatments for conditions associated with PCSK9 activity.

Latest Patents

Gopalakrishnan holds a patent for AX132 PCSK9 antagonists. This patent discloses antagonists that effectively inhibit PCSK9 function, presenting desirable options for treating various health conditions. The invention also includes nucleic acids encoding these antagonists, vectors, host cells, and compositions that comprise the antagonists. Additionally, methods for creating PCSK9-specific antagonists and their applications in inhibiting or antagonizing PCSK9 function are detailed in the patent.

Career Highlights

Gopalakrishnan is associated with Merck Sharp & Dohme Corporation, where he applies his expertise in biochemistry and pharmacology. His work at Merck has positioned him as a key player in the development of innovative therapeutic solutions.

Collaborations

Gopalakrishnan has collaborated with notable colleagues, including Peter Peizhi Luo and Kevin Caili Wang. These collaborations have likely contributed to the advancement of research and development in their field.

Conclusion

Gopalakrishnan Parthasarathy's contributions to the development of PCSK9 antagonists represent a significant advancement in medical science. His innovative work continues to pave the way for new treatments that can improve patient outcomes.